Heidelberg Pharma's lead ATAC candidate HDP-101 demonstrated safety and tolerability in cohort 7 at 112.50 µg/kg dose for multiple myeloma, with a patient from cohort 5 maintaining complete remission.
Heidelberg Pharma and HealthCare Royalty have amended their royalty financing agreement, providing an immediate $20 million payment to Heidelberg while restructuring future milestone payments.
Telix Pharmaceuticals and Grand Pharmaceutical Group initiate Phase III trial (ZIRCON-CP) in China for TLX250-CDx, a PET imaging agent for clear cell renal cell carcinoma (ccRCC).